Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPE for residual cardiovascular risk in acute coronary syndrome
ChiCTR2400081397Phase 4Recruiting
- Sponsor
- The Second Affiliated Hospital of Xi'an Jiaotong University
- Start
- Feb 2024
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of omega-3-acid triglycerides in acute coronary syndrome (ACS) (2 arms), sponsored by The Second Affiliated Hospital of Xi'an Jiaotong University. Primary endpoints: triglyceride, low density lipoprotein cholesterol (LDL-C) and 2 more. Started Feb 2024; status: recruiting.
02
Drugs
omega-3-acid triglycerides
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on ChiCTR2400081397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400081397.